Johnson & Johnson reports 96% of Sjögren’s patients prioritize mouth-dryness relief
AI Summary- Johnson & Johnson reported Phase 2 patient-experience findings for nipocalimab in Sjögren’s disease.
- Nipocalimab produced a 33% versus 16% salivary-flow response against placebo at Week 24.
- Two Phase 3 Sjögren’s disease studies are ongoing, including the DAFFODIL study.